Kelch-like protein 12 Antibodies

Kelch-like protein 12 (KLHL12)

Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that acts as a negative regulator of Wnt signaling pathway and ER-Golgi transport (PubMed:22358839, PubMed:27565346). The BCR(KLHL12) complex is involved in ER-Golgi transport by regulating the size of COPII coats, thereby playing a crucial role in collagen export, which is required for embryonic stem (ES) cells division: BCR(KLHL12) acts by mediating monoubiquitination of SEC31 (SEC31A or SEC31B) (PubMed:22358839, PubMed:27565346).

The BCR(KLHL12) complex is also involved in neural crest specification: in response to cytosolic calcium increase, interacts with the heterodimer formed with PEF1 and PDCD6/ALG-2, resulting in bridge together the BCR(KLHL12) complex and SEC31 (SEC31A or SEC31B), boosting monoubiquitination of SEC31 and subsequent collagen export (PubMed:27716508). Included in the BCR(KLHL12) complex, also acts as a negative regulator of the Wnt signaling pathway by mediating ubiquitination and subsequent proteolysis of DVL3 (PubMed:16547521).

Gene Information

Human
Gene Name:	KLHL12
Uniprot:	Q53G59
Entrez:	59349

Family

Belongs to:
No superfamily

Alternative Names

C3IP1kelch-like protein 12; CUL3-interacting protein 1; DKIR; FLJ27152; kelch-like 12 (Drosophila); kelch-like protein C3IP1

Molecular Weight

Mass (kDA):
63.277 kDA

Genomic Context

Human
Location:	1q32.1
Sequence:	1; NC_000001.11 (202891116..202928628, complement)

Tissue Specificity

Ubiquitously expressed. Highly expressed in testis and at lower levels in the submandibular salivary gland.

Subcellular Localizations

Cytoplasmic vesicle, COPII-coated vesicle.

Diseases

• Arthritis
• Dysplasia
• Malnutrition
• Sjogren's Syndrome
• Salivary Gland Diseases
• Neoplasms
• Lupus Erythematosus, Systemic
• Attention Deficit Hyperactivity Disorder
• Chylomicron Retention Disease

• Acute Interstitial Pneumonia
• Rheumatoid Arthritis
• Autoimmune Diseases

Interacting Proteins

• ATXN1
• BAG6
• C1QTNF2
• CCBE1
• COL8A1

• CUL3
• DVL3
• FGD2
• GLYCTK
• INMT

• KLHL2
• LNX1
• MPP1
• MRPL10
• PDGFRB

• PEF1
• PRR13
• RPP25L
• SDCBP
• SNX20

• SYNE4
• TBC1D10C
• TTBK2
• WDYHV1

Pathways

• Localization
• Transport
• Oocyte Development
• Secretion

PTMs

• Ubiquitination

Research Areas

• DNA Repair
• DNA replication, Transcription, Translation and Splicing

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/KLHL12

Best Uses Of The KLHL12 Marker

The Boster KLHL12 marker is a high quality primary antibody. It has been extensively cited by the research community in the last 25 years. These antibodies have been validated for use in Western Blotting, Immunohistochemistry, and ELISA. In addition to offering superior affinity and robust functionality, Boster antibodies are also highly specific, allowing for a higher level of detection.

Autoantibodies can be detected

Detection of autoantibodies in human serum is performed by identifying antibodies to KEICH-Like 12 (KLHL12), a PBC autoantigen. The microarray analysis was performed randomly from a pool that included sera. The results were presented as Autoantibody Units.

There are many types of antibodies that can be detected. KLHL12 is an example of an autoimmunity marker. An autoantibody can also be detected in the PBCs from patients with colorectal tumors. The method discloses the prognosis and stages of the disease. It also identifies the various treatment options available for different stages.

A recent study compared KLHL12's sensitivity and specificity for AMA detection of patients with PBC. The marker was highly sensitive to detect PBCs with AMA-negative status, and it could detect two of them. However, the test was inconclusive on HK1 as well as MIT3. The researchers concluded that AMA testing should be avoided in patients with a history autoimmunity.

A separate study of recombinant KLHL12 (recombinant protein) can be used to detect anti-KLHL12 antibodies. They were obtained at Abnova, Taipei (Taiwan). The KLHL12 Recombinant Protein Solution was added to flat bottom microtiter plates, which were then saturated with 1% BSA in PBS. The tested sera were then incubated at RT for 1 hour before horseradish peroxidase-conjugated human IgG antibodies were added to the plates. The TMB-bound human IgG antibodies then developed a color reaction and were stopped with 0.5 M H2SO4 (aqueous solution).

In the study, anti–KLHL12 antibody was detected in 30% patients with PBC. In contrast, the detection rate of anti-KLHL12 antibodies in non-PBC patients was only 17%. This means that anti-KLHL12 antibodies are highly specific for PBC. This means that they can increase the chances of identifying PBC by a high proportion of cases.

Patients with PBC who are AMA M2-negative have higher levels of anti-KLHL12 antibodies. They are significantly different from the M2-positive group, but AMA M2-negative patients were more likely to be positive for these antibodies. This research expands the diagnostic options for PBC. The presence anti-KLHL12 antibodies may aid in early detection. More research is needed to confirm that anti-KLHL12 antibodies are involved in this illness.

Application in immunoassays

Biomarkers are proteins found in tissues and bodily fluids that indicate specific diseases. This is an important part of immunoassays for the clinical diagnosis of disease. These biomarkers can then be detected using innovative immunoassays. Below are five areas where immunoassays can be used. Read on to discover more about these tools. You will also find their most popular uses.

This book also discusses optical detection systems in immunoassays. The book discusses the different optical detection systems, including surfaceplasmonresonance (SPR), used in immunoassay developing. The book also examines the challenges that may be encountered during assay development. This comprehensive guide provides information on the most common immunoassays used for SMCs. It will assist readers to optimize their assays and develop them for different applications.

You can use magnetic particle technology to enrich or decrease specific cell populations. This technology can be used in immunoassays to enrich or deplete specific cell populations. External magnets can be used to speed up the process of developing immunoassays. Nordic BioSite can help you learn more about magnetic particles for immunoassay applications.

Bioluminescence-based immunoassays have also been developed. These immunoassays utilize luciferase from bacteria to fuse protein A. Obelia longissima's Obelia longissima attaches obelin to the ZZ-domain. This combination produces a stable and long-lasting emission. The bioluminescent protein can detect antibodies against the target antigen.

Colorimetric immunoassays become more popular. They allow laboratories without the need for expensive equipment to detect the presence of a chemical such as AFP. An immunoassay can detect the concentration of an analyte in addition to measuring its presence. These techniques can detect the presence of certain drugs even without expensive medical equipment. This technique has obvious benefits.

These assays require labeling compounds. Labeled compounds can serve as competitive binding antigens. These labels may include biotin, luminescent, gold, and luminescent. A skilled technician will choose the right label for you and conduct the assay. An ELISA conventional test can take up to three days to provide an answer. The ILA format delivers similar results as the conventional format. These antibodies are useful both for diagnostic and research purposes.

Methods of detection

The KLHL12 protein is a highly expressed, highly conserved globular proteins that is involved muscle cell differentiation. It has been shown that it interacts with CUL3's ubiquitinligase through its Nterminal BTB domain. In addition, this gene has a direct effect on the myoD promoter, which is essential for skeletal muscle differentiation.

There are several ways to detect the KLHL12 marker. You can label the antibodies with a reporter dye, and analyze them using flow cytometric methods. Antibodies can be used to identify cellular localization of the protein. Boster has been offering high affinity primary antibodies for over 25 years. These antibodies are suitable to be used in Western Blotting and ELISA.

The results of these experiments indicate that CXCL12 treatment significantly increases the expression of KLHL12. Additionally, SB431542 inhibits CUL3 and GAPDH repression. The data in Table 1, are averages of three identical experiments. If this method gives false results, you should seek expert assistance. If you have any questions, feel free to contact us. We will be happy to help!

Methods for detecting KLHL12. This study revealed that antibodies against human HK1 were detected. The antibodies were used in the detection PBC and NK1.

Combining anti HK1 antibody with anti -KLHL12 antibody increased diagnostic sensitivity of PBC. Anti-HK1 antibodies are found in 1035% AMA-negative PBC patients. These two antibodies were combined with other markers increased the sensitivity of the test in AMA-negative patients. This test shows that the KLHL12 & HK1 antibodies can accurately detect PBC.

Figure 6 shows results of anti-HK1 antibodies and anti-KLHL12 antibody in PBC. Both types of antibodies were detected respectively in 16% and 25% of PBC cases. These results indicate that PBC patient cohorts had significantly higher levels of markers than non-PBC ones. However, the results of immunoblot and ELISA weren't significant.